ELADYNOS

This brand name is authorized in Austria, Croatia, Estonia, France, Ireland, Italy, Lithuania, Spain.

Active ingredients

The drug ELADYNOS contains one active pharmaceutical ingredient (API):

1	Abaloparatide UNII AVK0I6HY2U - ABALOPARATIDE
	Abaloparatide is a 34 amino acid peptide that shares 41% homology to parathyroid hormone [PTH] and 76% homology to parathyroid hormone related peptide [PTHrP(1-34)], and is an activator of the PTH1 receptor signalling pathway. Abaloparatide stimulates new bone formation on trabecular and cortical bone surfaces by stimulation of osteoblastic activity. Abaloparatide causes transient and limited increases in bone resorption and increases bone density.
	Read more about Abaloparatide

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
ELADYNOS Solution for injection	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
H05AA04		H Systemic hormonal preparations, excl. Sex hormones and insulins → H05 Calcium homeostasis → H05A Parathyroid hormones and analogues → H05AA Parathyroid hormones and analogues
Discover more medicines within H05AA04

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	3038611
ES	Centro de información online de medicamentos de la AEMPS	1221706001
FR	Base de données publique des médicaments	60276238
IT	Agenzia del Farmaco	050465018
LT	Valstybinė vaistų kontrolės tarnyba	1096127